Blockchain Registration Transaction Record

Oragenics Advances Concussion Drug ONP-002 in Phase IIa Trial

Oragenics (OGEN) provides shareholder update on Phase IIa trial of ONP-002 for concussion in Australia, plans FDA meeting; stock news.

This news matters because concussions and mild traumatic brain injuries affect millions worldwide, yet no FDA-approved treatments exist. Oragenics’ ONP-002 could become the first therapy to directly target the underlying brain injury, potentially reducing long-term cognitive impairments and improving recovery outcomes. The company’s progress in Australia and planned U.S. regulatory steps signal a possible breakthrough in neurological care, offering hope to patients, athletes, and military personnel who suffer from repeated head trauma.